{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:28:22Z","timestamp":1790659702330,"version":"4.1.0"},"reference-count":233,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T00:00:00Z","timestamp":1546473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["International Wound Journal"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:p>\n                    Pyoderma gangrenosum (PG) is a rare ulcerative skin disease that presents a therapeutic challenge. Tumour necrosis factor alpha (TNF\u03b1) inhibitors have been reported to successfully control PG. Our aim was to systematically evaluate and compare the clinical effectiveness of TNF\u03b1 inhibitors in adults with PG. A literature search including databases such as PubMed, Embase, Scopus, and Web of Science was conducted, using search terms related to PG and TNF\u03b1 inhibitors. Studies and case reports were included if patients were diagnosed with PG, over the age of 18 and administered TNF\u03b1 inhibitor. A total of 3212 unique citations were identified resulting in 222 articles describing 356 patients being included in our study. The study we report found an 87% (95% CI: 83%\u201090%) response rate and a 67% (95% CI: 62%\u201072%) complete response rate to TNF\u03b1 inhibitors. No statistically significant differences in the response rates (\n                    <jats:italic>P<\/jats:italic>\n                    = 0.6159) or complete response rates (\n                    <jats:italic>P<\/jats:italic>\n                    = 0.0773) to infliximab, adalimumab, and etanercept were found. In our study TNF\u03b1 inhibitors demonstrated significant effectiveness with response and complete response rates supporting the use of TNF\u03b1 inhibitors to treat PG in adults. Our study suggests that there is no significant difference in effectiveness among infliximab, adalimumab, and etanercept.\n                  <\/jats:p>","DOI":"10.1111\/iwj.13067","type":"journal-article","created":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T06:16:56Z","timestamp":1546496216000},"page":"511-521","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi\u2010systematic review"],"prefix":"10.1111","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4610-5428","authenticated-orcid":false,"given":"Hakim","family":"Ben Abdallah","sequence":"first","affiliation":[{"name":"Institute of Clinical Medicine, Aarhus Faculty of Health Sciences Aarhus University  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Fogh","sequence":"additional","affiliation":[{"name":"Department of Dermatology Aarhus University Hospital  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke","family":"Bech","sequence":"additional","affiliation":[{"name":"Department of Dermatology Aarhus University Hospital  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,1,3]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-136"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0356-7"},{"key":"e_1_2_7_4_1","first-page":"274","article-title":"The neutrophilic dermatoses","volume":"20","author":"Farhi D","year":"2008","journal-title":"Dermatol Nurs"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2008"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2008"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.5980"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1438269"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.074815"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2958"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"e_1_2_7_12_1","unstructured":"Business Insider. One of the world's blockbuster drugs might not exist if its research hadn't flopped in a major way 2015 2018"},{"key":"e_1_2_7_13_1","unstructured":"EurekAlert!: REMICADE becomes first anti\u2010TNF biologic therapy to treat 1 million patients worldwide 2007 2018."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13740"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjps.2017.08.013"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.08.020"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.08.009"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.05.005"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-018-4971-1"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijscr.2018.02.026"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13503"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.12746"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13591"},{"key":"e_1_2_7_24_1","first-page":"36","article-title":"Non\u2010response to Interleukin\u20101 antagonist Canakinumab in two patients with refractory pyoderma gangrenosum and hidradenitis Suppurativa","volume":"10","author":"Sun NZ","year":"2017","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.03.016"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15740"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13976"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2017.12.009"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2017.1306071"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15226"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2017.29.2.260"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.14309\/00000434-201710001-01974"},{"key":"e_1_2_7_33_1","first-page":"19","article-title":"The successful management of PASH syndrome with biologics: a case report","volume":"26","author":"Karciauskiene J","year":"2017","journal-title":"Exp Dermatol"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13856"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.01.004"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13086"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.02.005"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.5070\/D32312037669"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001100"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000511"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12498"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.47102\/annals-acadmedsg.V45N12p569"},{"key":"e_1_2_7_43_1","first-page":"197","article-title":"Prednisone combined with etanercept for the treatment of psoriatic arthritis accompanied by pyoderma gangrenosum","volume":"45","author":"Wu C","year":"2016","journal-title":"J Clin Dermatol"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.02.156"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.464"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00108-015-0004-8"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000941"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.09.009"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00238-015-1147-5"},{"key":"e_1_2_7_50_1","first-page":"ic44","article-title":"Severe bilateral lower extremity pyoderma gangrenosum","volume":"16","author":"Laun J","year":"2016","journal-title":"Eplasty"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2015.12.004"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/jscr\/rjw103"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2016.1174327"},{"key":"e_1_2_7_54_1","first-page":"57","article-title":"Topical crushed prednisolone use in recalcitrant peristomal pyoderma gangrenosum","volume":"57","author":"Jeffery T","year":"2016","journal-title":"Australas J Dermatol"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2015.1034075"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12387"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2016.07.007"},{"key":"e_1_2_7_58_1","first-page":"83","article-title":"Generalized pyoderma gangrenosum associated with ulcerative colitis: successful treatment with infliximab and azathioprine","volume":"24","author":"Chatzinasiou F","year":"2016","journal-title":"Acta dermatovenerol Croat"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2016.14.4.365"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13265"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.3315\/jdcr.2015.1206"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1929"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.06.054"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12765"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.10.002"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.54.4853"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rce.2014.09.006"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2015.05.001"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12928"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-014-2110-9"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1391120"},{"key":"e_1_2_7_72_1","first-page":"19184","article-title":"Pyoderma gangrenosum of articulations carpi associated with ulcerative colitis: one case report","volume":"8","author":"Meng X","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.344"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.02.012"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.02.625"},{"key":"e_1_2_7_76_1","first-page":"337","article-title":"Hidradenitis suppurativa and concomitant pyoderma gangrenosum treated with infliximab","volume":"95","author":"Groleau PF","year":"2015","journal-title":"Cutis"},{"key":"e_1_2_7_77_1","doi-asserted-by":"publisher","DOI":"10.1159\/000369965"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S61202"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.12.016"},{"key":"e_1_2_7_80_1","first-page":"67","article-title":"Successful treatment of pyoderma gangrenosum with the interleukin\u20101 receptor antagonist anakinra: a case series of three patients","volume":"173","author":"Chin MF","year":"2015","journal-title":"Br J Dermatol"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.4321\/S0376-78922015000100012"},{"key":"e_1_2_7_82_1","first-page":"e269","article-title":"Cutaneous manifestations and gastrointestinal disorders: report of two emblematic cases","volume":"166","author":"Carlesimo M","year":"2015","journal-title":"Clin Ter"},{"key":"e_1_2_7_83_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12703"},{"key":"e_1_2_7_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2014.12.003"},{"key":"e_1_2_7_85_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/461467"},{"key":"e_1_2_7_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.06.003"},{"key":"e_1_2_7_87_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10151-014-1192-2"},{"key":"e_1_2_7_88_1","first-page":"104","article-title":"A refractory case of pyoderma gangrenosum responding to infliximab","volume":"41","author":"So BJ","year":"2014","journal-title":"J Dermatol"},{"key":"e_1_2_7_89_1","first-page":"105","article-title":"The management of peristomal pyoderma gangrenosum in a patient suffering from colon Crohn's disease: a case report","volume":"8","author":"Pileri F","year":"2014","journal-title":"Ital J Med"},{"key":"e_1_2_7_90_1","doi-asserted-by":"publisher","DOI":"10.2174\/1874372201408010068"},{"key":"e_1_2_7_91_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12394"},{"key":"e_1_2_7_92_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000187"},{"key":"e_1_2_7_93_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12570-013-0195-1"},{"key":"e_1_2_7_94_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-014-0044-3"},{"key":"e_1_2_7_95_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12274"},{"key":"e_1_2_7_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12393"},{"key":"e_1_2_7_97_1","first-page":"285","article-title":"Peri\u2010ileostomy pyoderma gangrenosum","volume":"106","author":"Cerdan\u2010Santacruz C","year":"2014","journal-title":"Case report Rev Esp Enferm Dig"},{"key":"e_1_2_7_98_1","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2014.12.2.153"},{"key":"e_1_2_7_99_1","doi-asserted-by":"publisher","DOI":"10.4067\/S0718-40262014000300013"},{"key":"e_1_2_7_100_1","first-page":"E26","article-title":"Chronically\u2010ulcerating pyoderma gangrenosum: successful healing under infliximab\u2010therapy","volume":"12","author":"Almoshawer E","year":"2014","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_7_101_1","doi-asserted-by":"crossref","first-page":"S421","DOI":"10.14309\/00000434-201310001-01419","article-title":"A case report of a patient with Crohn's disease complicated by pyoderma gangrenosum treated with intravenous immunoglobulin","volume":"108","author":"Yoo L","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_7_102_1","doi-asserted-by":"publisher","DOI":"10.4067\/S0034-98872013000900008"},{"key":"e_1_2_7_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0121-8123(13)70129-4"},{"key":"e_1_2_7_104_1","doi-asserted-by":"publisher","DOI":"10.4045\/tidsskr.13.0808"},{"key":"e_1_2_7_105_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-6-19"},{"key":"e_1_2_7_106_1","doi-asserted-by":"publisher","DOI":"10.12968\/jowc.2013.22.2.68"},{"key":"e_1_2_7_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1873-9946(13)60744-8"},{"key":"e_1_2_7_108_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2011.05201.x"},{"key":"e_1_2_7_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2012.07.029"},{"key":"e_1_2_7_110_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12042"},{"key":"e_1_2_7_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcol.2013.08.010"},{"key":"e_1_2_7_112_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-012-0640-y"},{"key":"e_1_2_7_113_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12359"},{"key":"e_1_2_7_114_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1501-8"},{"key":"e_1_2_7_115_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12380"},{"key":"e_1_2_7_116_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2013-201084"},{"key":"e_1_2_7_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2012.07.021"},{"key":"e_1_2_7_118_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.04.005"},{"key":"e_1_2_7_119_1","doi-asserted-by":"publisher","DOI":"10.14309\/00000434-201210001-01265"},{"key":"e_1_2_7_120_1","doi-asserted-by":"publisher","DOI":"10.5070\/D39C8094S3"},{"key":"e_1_2_7_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2011.04.010"},{"key":"e_1_2_7_122_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21915"},{"key":"e_1_2_7_123_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2011.04219.x"},{"key":"e_1_2_7_124_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcpc1104568"},{"key":"e_1_2_7_125_1","first-page":"1050","article-title":"Pustular pyoderma gangrenosum associated with ulcerative colitis","volume":"50","author":"Kim YH","year":"2012","journal-title":"Kor J Dermatol"},{"key":"e_1_2_7_126_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2011.04234.x"},{"key":"e_1_2_7_127_1","first-page":"93","article-title":"Crohn's disease associated pyoderma gangrenosum treated with adalimumab","volume":"29","author":"Kakagia D","year":"2012","journal-title":"Balkan Med J"},{"key":"e_1_2_7_128_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.09.032"},{"key":"e_1_2_7_129_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-012-0006-6"},{"key":"e_1_2_7_130_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2011.01346.x"},{"key":"e_1_2_7_131_1","first-page":"175","article-title":"Treatment of thalidomide resistant pyoderma gangrenosum with etenercept","volume":"20","author":"Guedes R","year":"2012","journal-title":"Acta Dermatovenerol Croat"},{"key":"e_1_2_7_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.04.045"},{"key":"e_1_2_7_133_1","first-page":"332","article-title":"Infliximab treatment in resistant pyoderma gangrenosum: a case report","volume":"58","author":"Durmaz Y","year":"2012","journal-title":"Turkiye Fiziksel Tip ve Rehabilitasyon Dergisi"},{"key":"e_1_2_7_134_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1301"},{"key":"e_1_2_7_135_1","doi-asserted-by":"publisher","DOI":"10.3109\/01676830.2011.648810"},{"key":"e_1_2_7_136_1","first-page":"31","article-title":"Successful infliximab therapy for hidradenitis suppurativa and pyoderma gangrenosum, complicated by development of palmo\u2010plantar pustular psoriasis: case report and literature review","volume":"53","author":"Choi SD","year":"2012","journal-title":"Australas J Dermatol"},{"key":"e_1_2_7_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2011.07.003"},{"key":"e_1_2_7_138_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e318278b84c"},{"key":"e_1_2_7_139_1","first-page":"297","article-title":"Superficial pyoderma gangrenosum treated with infliximab: a case report","volume":"90","author":"Bhatti H","year":"2012","journal-title":"Cutis"},{"key":"e_1_2_7_140_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2011.04.004"},{"key":"e_1_2_7_141_1","first-page":"S113","article-title":"A threat to life and limb: a case of sepsis and osteomyelitis in a patient with undiagnosed pyoderma gangrenosum","volume":"59","author":"Thornton K","year":"2011","journal-title":"J Am Geriatr Soc"},{"key":"e_1_2_7_142_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21778"},{"key":"e_1_2_7_143_1","first-page":"788","article-title":"Severe colitis with pyoderma gangrenosum after ipilimumab treatment in a melanoma patient with colostomy\u2010a therapeutic challenge","volume":"9","author":"Rudolph B","year":"2011","journal-title":"JDDG"},{"key":"e_1_2_7_144_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2011.04887.x"},{"key":"e_1_2_7_145_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2010.01387.x"},{"key":"e_1_2_7_146_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21684"},{"key":"e_1_2_7_147_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546631003797106"},{"key":"e_1_2_7_148_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2010.01009.x"},{"key":"e_1_2_7_149_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-1168-0"},{"key":"e_1_2_7_150_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASW.0000397898.56121.3f"},{"key":"e_1_2_7_151_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21723"},{"key":"e_1_2_7_152_1","first-page":"35","article-title":"Novel combination of intravenous immunoglobulin and rituximab in the treatment of recalcitrant pyoderma gangrenosum","volume":"165","author":"Bennett M","year":"2011","journal-title":"Br J Dermatol"},{"key":"e_1_2_7_153_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3181e969b9"},{"key":"e_1_2_7_154_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-010-0336-0"},{"key":"e_1_2_7_155_1","first-page":"94","article-title":"Parastomal pyoderma gangrenosum successfully treated with adalimumab","volume":"163","author":"Ryan A","year":"2010","journal-title":"Br J Dermatol"},{"key":"e_1_2_7_156_1","doi-asserted-by":"publisher","DOI":"10.5070\/D34PH5R1M2"},{"key":"e_1_2_7_157_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rce.2009.11.021"},{"key":"e_1_2_7_158_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.328"},{"key":"e_1_2_7_159_1","doi-asserted-by":"publisher","DOI":"10.1177\/1090820X10366011"},{"key":"e_1_2_7_160_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2010.01357.x"},{"key":"e_1_2_7_161_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.2293"},{"key":"e_1_2_7_162_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0540"},{"key":"e_1_2_7_163_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2009.04.005"},{"key":"e_1_2_7_164_1","first-page":"343","article-title":"A case of recalcitrant pyoderma gangrenosum treated by infliximab","volume":"47","author":"Jung HD","year":"2009","journal-title":"Kor J Dermatol"},{"key":"e_1_2_7_165_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.136.4_MeetingAbstracts.19S-d"},{"key":"e_1_2_7_166_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2009.57"},{"key":"e_1_2_7_167_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20748"},{"key":"e_1_2_7_168_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2008.03018.x"},{"key":"e_1_2_7_169_1","first-page":"26","article-title":"Pyoderma gangrenosum in a patient with Bruton's X\u2010linked Agammaglobulinemia: shared pathogenesis of altered tumor necrosis factor alpha?","volume":"1","author":"Schwartzfarb EM","year":"2008","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_7_170_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjps.2006.11.011"},{"key":"e_1_2_7_171_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-7310(08)76179-9"},{"key":"e_1_2_7_172_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2007.07.023"},{"key":"e_1_2_7_173_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2007.02607.x"},{"key":"e_1_2_7_174_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08433.x"},{"key":"e_1_2_7_175_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2008.03412.x"},{"key":"e_1_2_7_176_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2008.02756.x"},{"key":"e_1_2_7_177_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.02094_14.x"},{"key":"e_1_2_7_178_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20481"},{"key":"e_1_2_7_179_1","doi-asserted-by":"publisher","DOI":"10.1159\/000111515"},{"key":"e_1_2_7_180_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-007-0733-8"},{"key":"e_1_2_7_181_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08212.x"},{"key":"e_1_2_7_182_1","doi-asserted-by":"publisher","DOI":"10.1159\/000108637"},{"key":"e_1_2_7_183_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2007.03293.x"},{"key":"e_1_2_7_184_1","doi-asserted-by":"publisher","DOI":"10.1159\/000106584"},{"key":"e_1_2_7_185_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.2007.00344.x"},{"key":"e_1_2_7_186_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.3.306"},{"key":"e_1_2_7_187_1","doi-asserted-by":"publisher","DOI":"10.1177\/1534734607300912"},{"key":"e_1_2_7_188_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20081"},{"key":"e_1_2_7_189_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20181"},{"key":"e_1_2_7_190_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2007.03286.x"},{"key":"e_1_2_7_191_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01528_8.x"},{"key":"e_1_2_7_192_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.12.1168"},{"key":"e_1_2_7_193_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.10.058"},{"key":"e_1_2_7_194_1","doi-asserted-by":"publisher","DOI":"10.1080\/00015550510040923"},{"key":"e_1_2_7_195_1","doi-asserted-by":"publisher","DOI":"10.1097\/00152192-200609000-00013"},{"key":"e_1_2_7_196_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2005.01972.x"},{"key":"e_1_2_7_197_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.104943"},{"key":"e_1_2_7_198_1","first-page":"e8","article-title":"Adalimumab therapy for recalcitrant pyoderma gangrenosum","volume":"5","author":"Fonder MA","year":"2006","journal-title":"J Burns Wounds"},{"key":"e_1_2_7_199_1","first-page":"173","article-title":"Infliximab for treatment of resistant pyoderma gangrenosum associated with Crohn's disease","volume":"15","author":"Ferkolj I","year":"2006","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"e_1_2_7_200_1","doi-asserted-by":"publisher","DOI":"10.2478\/s11536-006-0024-9"},{"key":"e_1_2_7_201_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2004.01716.x"},{"key":"e_1_2_7_202_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.2005.00170.x"},{"key":"e_1_2_7_203_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2004.01681.x"},{"key":"e_1_2_7_204_1","doi-asserted-by":"publisher","DOI":"10.1080\/03009740510026698"},{"key":"e_1_2_7_205_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.10.014"},{"key":"e_1_2_7_206_1","first-page":"1968","article-title":"Treatment with infliximab of peristomal pyoderma gangrenosum in ulcerative colitis","volume":"167","author":"Krag AA","year":"2005","journal-title":"Ugeskr Laeger"},{"key":"e_1_2_7_207_1","first-page":"401","article-title":"Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report","volume":"14","author":"Kouklakis G","year":"2005","journal-title":"Rom J Gastroenterol"},{"key":"e_1_2_7_208_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06812.x"},{"key":"e_1_2_7_209_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-004-0467-8"},{"key":"e_1_2_7_210_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06467.x"},{"key":"e_1_2_7_211_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630500424722"},{"key":"e_1_2_7_212_1","first-page":"666","article-title":"Peristomal pyoderma gangrenosum: clinical features and response to infliximab therapy","volume":"48","author":"George B","year":"2005","journal-title":"Dis Colon Rectum"},{"key":"e_1_2_7_213_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2004.01470.x"},{"key":"e_1_2_7_214_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:DDAS.0000042245.20042.4f"},{"key":"e_1_2_7_215_1","doi-asserted-by":"publisher","DOI":"10.4321\/S1130-01082004000600008"},{"key":"e_1_2_7_216_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2004.03551.x"},{"key":"e_1_2_7_217_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2003.05760.x"},{"key":"e_1_2_7_218_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.rhu.0000111315.94725.9c"},{"key":"e_1_2_7_219_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-481x.2004.0002.x"},{"key":"e_1_2_7_220_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07581.x"},{"key":"e_1_2_7_221_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05294.x"},{"key":"e_1_2_7_222_1","first-page":"49","article-title":"Infliximab: a treatment option for ulcerative pyoderma gangrenosum","volume":"15","author":"Geren SM","year":"2003","journal-title":"Wounds"},{"key":"e_1_2_7_223_1","first-page":"S175","article-title":"Treatment of peristomal pyoderma gangrenosum associated with Crohn's disease with infliximab","volume":"98","author":"Finkelstein W","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_7_224_1","doi-asserted-by":"publisher","DOI":"10.1080\/gas.37.7.863.865"},{"key":"e_1_2_7_225_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200208000-00021"},{"key":"e_1_2_7_226_1","doi-asserted-by":"publisher","DOI":"10.1080\/003655202320378338"},{"key":"e_1_2_7_227_1","doi-asserted-by":"publisher","DOI":"10.1159\/000065860"},{"key":"e_1_2_7_228_1","first-page":"A618","article-title":"Cutaneous manifestations of inflammatory bowel disease improve with infliximab therapy","volume":"122","author":"Foster EN","year":"2002","journal-title":"Gastroenterology"},{"key":"e_1_2_7_229_1","first-page":"930","article-title":"Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti\u2010tumor necrosis factor alpha monoclonal antibody","volume":"137","author":"Tan MH","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_7_230_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1072-7515(01)01081-X"},{"key":"e_1_2_7_231_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(01)83090-0"},{"key":"e_1_2_7_232_1","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.135.5.564"},{"key":"e_1_2_7_233_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.12.1546"},{"key":"e_1_2_7_234_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-013-2762-2"}],"container-title":["International Wound Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fiwj.13067","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iwj.13067","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/iwj.13067","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iwj.13067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T09:38:26Z","timestamp":1748338706000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iwj.13067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,3]]},"references-count":233,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1111\/iwj.13067"],"URL":"https:\/\/doi.org\/10.1111\/iwj.13067","archive":["Portico"],"relation":{},"ISSN":["1742-4801","1742-481X"],"issn-type":[{"value":"1742-4801","type":"print"},{"value":"1742-481X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,3]]},"assertion":[{"value":"2018-11-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}